Femasys (FEMY) Cash from Financing Activities (2020 - 2026)
Femasys (FEMY) reported Cash from Financing Activities of $342334.0 for Q1 2026, down 93.45% on a YoY basis from $5.2 million in Q1 2025, and down 96.23% quarter-over-quarter from $9.1 million in Q4 2025.
Femasys (FEMY) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Femasys has reported Cash from Financing Activities for 7 years, with the latest figure at $342334.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 93.45% year-over-year to $342334.0; the trailing twelve-month figure through Mar 2026 stood at $20.2 million (up 212.48% YoY), and the FY2025 full-year result was $25.1 million, up 1139.74% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $342334.0, down from $9.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $16.1 million in Q4 2023, with the low at -$362039.0 in Q3 2022.
- Historically, Cash from Financing Activities has averaged $2.9 million across 5 years, with a median of $824252.0 in 2023.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.32% — and 2023, when it surged 19751.64%.
- Femasys' Cash from Financing Activities stood at -$81950.0 in 2022, then surged by 19751.64% to $16.1 million in 2023, then sank by 93.63% to $1.0 million in 2024, then surged by 785.15% to $9.1 million in 2025, then plunged by 96.23% to $342334.0 in 2026.
- The last three Cash from Financing Activities figures came in at $342334.0 (Q1 2026), $9.1 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Femasys | 254.59 Mn | 249.20 Mn | - | 342,334.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 342,334.00 |
| Mar 31, 2026 | 342,334.00 |
| Dec 31, 2025 | 9.08 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Jun 30, 2024 | 223,549.00 |
| Jun 30, 2024 | 223,549.00 |
| Mar 31, 2024 | 778,175.00 |
| Mar 31, 2024 | 778,175.00 |
| Dec 31, 2023 | 16.10 Mn |
| Dec 31, 2023 | 16.10 Mn |
| Sep 30, 2023 | 870,329.00 |
| Sep 30, 2023 | 870,329.00 |